Skip to main content
Fig. 3 | Journal for ImmunoTherapy of Cancer

Fig. 3

From: Plasmacytoid dendritic cells orchestrate innate and adaptive anti-tumor immunity induced by oncolytic coxsackievirus A21

Fig. 3

CVA21 treatment enhances NK cell activation and function. a. CD69 expression on healthy donor NK cells (CD3CD56+) following CVA21 treatment for 48 h (n = 4). b. Healthy donor PBMC (± 0.1 pfu/cell CVA21) were co-cultured at a 2:1 ratio with AML or MM target cells for 5 h and the percentage of NK cells expressing CD107a/b was determined (n = 4); data for CVA21-sensitive (right) and CVA21-resistant (left) cell lines are shown. c. CVA21-sensitive (right) and CVA21-resistant (left) cell lines were labelled with 51Cr and then co-cultured with healthy donor PBMC (±CVA21 treatment) for 4 h and the percentage lysis of target cells was determined (n = 4). Error bars indicate SEM. *denotes statistical significance

Back to article page